doctor NO
NO nel DNA
Toh chi si vede è tornato il buffone del circo
hai iniziato la tournée in giro per i siti
NicOx : Garufi ... e la Rivoluzione Pharma (43 lettori)
- Creatore Discussione Yesod
- Data di Inizio
- Stato
Toh chi si vede è tornato il buffone del circo
hai iniziato la tournée in giro per i siti
doctor NO
NO nel DNA
Solo sopra i 10 ..............deve bucare o torna indietro !!
L'importante è che le compri anche sopra i 10€
sai com'è ci tengo a fare la crociera dei 100€ e poi sai che bello ne scegliamo una con partenza da Genova cosi salutiamo la pantegana volante che ci farà ciao con l'aluccia
dal suo container
piazzato sulle banchine dei camalli
doctor NO
NO nel DNA
se proprio non vuole tornarci può sempre venire a conoscermi di persona all'AG del 17 giugno in quel di Sophie Anthipolistorna nella gabbietta!!!!!!
Sai sono curioso di vedere la faccia di un BASHER probabilmente non sarà erectus
ma arriverà strisciando sul terreno
SIETE PRONTI? 
DickSIM
Prima o poi....ci becco!
ATTENZIONE ATTENZIONE...........MERCK STA RICARICANDO LE ARMI DOPO IL FLOP NOVO CARDIA , E OLTRE A COX 
HA SPARATO UNA CARTUCCIA OGGI.........
Merck inks drug discovery deal with Xenon
June 11, 2009 — 8:55am ET
Merck has signed a deal with Canada-based Xenon to discover and develop small molecule candidates for cardiovascular disease. Xenon, a clinical genetics-based drug discovery and development outfit, will perform validation studies using its clinical genetics platform, as well as drug discovery. The company will handle certain preclinical development of small molecule compounds for selected targets. Merck has exclusive rights to any drug resulting from the collaboration, though Xenon can develop candidates which Merck passes over.
Though the total value of the deal was not disclosed, Xenon said it will receive $95.5 million for the first target and up to $89.5 million for each subsequent target selected for drug discovery. Additionally, Merck will pay Xenon undisclosed royalties on sales of products resulting from the collaboration.
"This new alliance, which represents our fifth partnership with a major pharmaceutical company, once again highlights Xenon's R&D capabilities and validates our drug discovery platform," said Michael Hayden, CSO of Xenon. The company has previously partnered with the likes of Roche and Takeda on similar projects.
HA SPARATO UNA CARTUCCIA OGGI......... Merck inks drug discovery deal with Xenon
June 11, 2009 — 8:55am ET
Merck has signed a deal with Canada-based Xenon to discover and develop small molecule candidates for cardiovascular disease. Xenon, a clinical genetics-based drug discovery and development outfit, will perform validation studies using its clinical genetics platform, as well as drug discovery. The company will handle certain preclinical development of small molecule compounds for selected targets. Merck has exclusive rights to any drug resulting from the collaboration, though Xenon can develop candidates which Merck passes over.
Though the total value of the deal was not disclosed, Xenon said it will receive $95.5 million for the first target and up to $89.5 million for each subsequent target selected for drug discovery. Additionally, Merck will pay Xenon undisclosed royalties on sales of products resulting from the collaboration.
"This new alliance, which represents our fifth partnership with a major pharmaceutical company, once again highlights Xenon's R&D capabilities and validates our drug discovery platform," said Michael Hayden, CSO of Xenon. The company has previously partnered with the likes of Roche and Takeda on similar projects.
ugotega
Forumer storico
tratto da bourso:
News EULAR Auj. à 19:53
THU0341
A RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO AND NAPROXEN
CONTROLLED, MULTICENTER PHASE 3 STUDY OF NAPROXCINOD IN SUBJECTS WITH
OSTEOARTHRITIS OF THE KNEE: EFFICACY RESULTS FOLLOWING 13-WEEK TREATMENTC. E. Marrero1, C. Tuten2, T. Shamin3, V. Awasty4, J. Agaiby5, D. Hassman6, J. Sutphen7, H. Frayssinet8, B. Duquesroix*8
1Medicine, Deep South Clinical Research, Nederland, 2Medicine, Clinical Center of Asheville, Asheville, 3Medicine, Heartland Clinical Research, Omaha, 4Internal Medicine, R & R Research, Marion, 5Medicine, Clinical Investigation Specialist Inc, Gurnee, 6Medicine, Comprehensive Clinical Research, Berlin, 7Research and Development, NicOx Inc, Warren, United States, 8Research and Development, NicOx SA, Sophia Antipolis, France
Background:
Naproxcinod is a Cycloxygenase Inhibiting Nitric Oxide Donator (CINOD)
under development for the relief of signs and symptoms of OA. In
previous trials naproxcinod has shown anti-inflammatory and analgesic
properties similar to traditional NSAIDs and COX2 inhibitors associated
with a favorable safety and tolerability profile.
Objectives:
The primary objective of the study was to show that naproxcinod 375 mg
bid and 750 mg bid were superior to placebo in relieving signs and
symptoms in subjects with OA of the knee at Week 13.
Methods:
Subjects (40+ years of age) meeting ACR criteria for knee OA and
experiencing a flare of pain at baseline after discontinuation of
previous analgesic treatment were randomized (1:1:1:1) to either
naproxcinod 375 mg or 750 mg bid, naproxen 500 mg bid or placebo bid.
The three co-primary efficacy variables were the mean change from
Baseline to Week 13 in WOMAC™ pain and function subscale scores and
subject’s global assessment of disease status to compare naproxcinod
with placebo for superiority.
The analysis of each primary
efficacy variable was based on an analysis of covariance (ANCOVA) model
with treatment group and center as factors, and baseline value as
covariate. The primary efficacy analysis was performed using the
Intent-to-Treat (ITT) population and was performed on as-randomized
basis.
Results:
The ITT population consisted of 1011 subjects from 129 centers in the
US. 71.0% of subjects were female, 78.9% Caucasian; mean age was 59.8
years, mean BMI 33.8 kg/m2. At Week 13, 766 subjects completed the
study (75.8%).
Both doses of naproxcinod (375 mg bid and 750 mg
bid) demonstrated superior efficacy to placebo in the three co-primary
endpoints of WOMAC™ pain and function, and subject’s overall rating of
disease status (pPercent
of subjects with at least 1 AE was 47.0%, 46.4%, for naproxcinod 375
and 750 mg bid, respectively, 47.7% for naproxen and 44.8% for placebo.
Conclusion:
This study demonstrated the clinical efficacy of both naproxcinod doses
over placebo, confirming the results of previous trials. Treatments
were safe and well tolerated.
References: Study HCT 3012-X-302. First 13 weeks of treatment.
Disclosure of Interest: CEM, CT, TS, VA, JA, DH were investigators in this NicOx' sponsored study.
JS, HF, DB are Nicox' employees.
News EULAR Auj. à 19:53
THU0341
A RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO AND NAPROXEN
CONTROLLED, MULTICENTER PHASE 3 STUDY OF NAPROXCINOD IN SUBJECTS WITH
OSTEOARTHRITIS OF THE KNEE: EFFICACY RESULTS FOLLOWING 13-WEEK TREATMENTC. E. Marrero1, C. Tuten2, T. Shamin3, V. Awasty4, J. Agaiby5, D. Hassman6, J. Sutphen7, H. Frayssinet8, B. Duquesroix*8
1Medicine, Deep South Clinical Research, Nederland, 2Medicine, Clinical Center of Asheville, Asheville, 3Medicine, Heartland Clinical Research, Omaha, 4Internal Medicine, R & R Research, Marion, 5Medicine, Clinical Investigation Specialist Inc, Gurnee, 6Medicine, Comprehensive Clinical Research, Berlin, 7Research and Development, NicOx Inc, Warren, United States, 8Research and Development, NicOx SA, Sophia Antipolis, France
Background:
Naproxcinod is a Cycloxygenase Inhibiting Nitric Oxide Donator (CINOD)
under development for the relief of signs and symptoms of OA. In
previous trials naproxcinod has shown anti-inflammatory and analgesic
properties similar to traditional NSAIDs and COX2 inhibitors associated
with a favorable safety and tolerability profile.
Objectives:
The primary objective of the study was to show that naproxcinod 375 mg
bid and 750 mg bid were superior to placebo in relieving signs and
symptoms in subjects with OA of the knee at Week 13.
Methods:
Subjects (40+ years of age) meeting ACR criteria for knee OA and
experiencing a flare of pain at baseline after discontinuation of
previous analgesic treatment were randomized (1:1:1:1) to either
naproxcinod 375 mg or 750 mg bid, naproxen 500 mg bid or placebo bid.
The three co-primary efficacy variables were the mean change from
Baseline to Week 13 in WOMAC™ pain and function subscale scores and
subject’s global assessment of disease status to compare naproxcinod
with placebo for superiority.
The analysis of each primary
efficacy variable was based on an analysis of covariance (ANCOVA) model
with treatment group and center as factors, and baseline value as
covariate. The primary efficacy analysis was performed using the
Intent-to-Treat (ITT) population and was performed on as-randomized
basis.
Results:
The ITT population consisted of 1011 subjects from 129 centers in the
US. 71.0% of subjects were female, 78.9% Caucasian; mean age was 59.8
years, mean BMI 33.8 kg/m2. At Week 13, 766 subjects completed the
study (75.8%).
Both doses of naproxcinod (375 mg bid and 750 mg
bid) demonstrated superior efficacy to placebo in the three co-primary
endpoints of WOMAC™ pain and function, and subject’s overall rating of
disease status (pPercent
of subjects with at least 1 AE was 47.0%, 46.4%, for naproxcinod 375
and 750 mg bid, respectively, 47.7% for naproxen and 44.8% for placebo.
Conclusion:
This study demonstrated the clinical efficacy of both naproxcinod doses
over placebo, confirming the results of previous trials. Treatments
were safe and well tolerated.
References: Study HCT 3012-X-302. First 13 weeks of treatment.
Disclosure of Interest: CEM, CT, TS, VA, JA, DH were investigators in this NicOx' sponsored study.
JS, HF, DB are Nicox' employees.
sustazz
Nuovo forumer
----------------- AVVISO AI NAVIGANTI ---------------
Ognuno è responsabile delle proprie AZIONI
Ognuno è responsabile delle proprie AZIONI
Ognuno è responsabile delle proprie AZIONI
-----------------------------------------------------------
-Nicox rapportera très prochainement (2 à 3 ans maxi) des dividendes aux actionnaires et donc au FSI.
"------- Nicox riporterà fra molto breve (2 a 3 anni maxi) dei dividendi agli azionisti e dunque alla FSI--- "
Netzach
Forumer storico
----------------- AVVISO AI NAVIGANTI ---------------
Ognuno è responsabile delle proprie AZIONI
Ognuno è responsabile delle proprie AZIONI
Ognuno è responsabile delle proprie AZIONI
-----------------------------------------------------------
-Nicox rapportera très prochainement (2 à 3 ans maxi) des dividendes aux actionnaires et donc au FSI.
"------- Nicox riporterà fra molto breve (2 a 3 anni maxi) dei dividendi agli azionisti e dunque alla FSI--- "
Non divulgare notizie riservate ...
guly
Forumer storico
----------------- AVVISO AI NAVIGANTI ---------------
Ognuno è responsabile delle proprie AZIONI
Ognuno è responsabile delle proprie AZIONI
Ognuno è responsabile delle proprie AZIONI
-----------------------------------------------------------
-Nicox rapportera très prochainement (2 à 3 ans maxi) des dividendes aux actionnaires et donc au FSI.
"------- Nicox riporterà fra molto breve (2 a 3 anni maxi) dei dividendi agli azionisti e dunque alla FSI--- "
FSI sarebbe?
- Stato